益肾健脾丸防治肠癌FOLFIRI方案化疗后骨髓抑制的疗效分析  

The efficacy of Yishen Jianpi Wan in preventing and treating myelosuppression after FOLFIRI chemotherapy for colorectal cancer

作　　者：张丽榕 林飞[2] ZHANG Lirong;LIN Fei

机构地区：[1]福建省三明市中西医结合医院,福建三明365000 [2]中国中医科学院广安门医院,北京100053

出　　处：《中医临床研究》2023年第6期82-85,共4页Clinical Journal Of Chinese Medicine

摘　　要：目的:本研究旨在观察益肾健脾丸对结直肠癌患者接受FOLFIRI方案化疗前后骨髓抑制的临床疗效。方法:收集2020年8月1日―2022年4月1日在三明市中西医结合医院肿瘤综合治疗科住院的病理证实为结直肠癌,并行FOLFIRI方案化疗的患者60例,采用随机数字表法分为两组,每组30例,对照组单一接受FOLFIRI方案化疗,试验组在化疗基础上联用益肾健脾丸。对比观察两组化疗前和化疗后第7天生活质量卡氏评分、中医临床证候积分、外周血中白细胞计数(White Blood Cell Count,WBC)、血小板计数(Platelet Count,PLT)、血红蛋白(Hemoglobin,HGB)的变化情况。结果:治疗后两组卡氏评分、中医临床证候积分存在差异(P<0.05),试验组较对照组改善;治疗后两组血常规中WBC比较,差异有统计学意义(P<0.05),试验组WBC下降的幅度更小,而HGB、PLT水平在治疗前后的差异不明显(P>0.05);试验组骨髓抑制的总发生率更低。结论:化疗后骨髓抑制的病机以虚为主,治疗通过健运脾胃、补益肝肾可以促进血液化生,刺激骨髓造血。益肾健脾丸汇巴戟天、菟丝子、女贞子、黄精等阴阳并补,集四君、豆蔻、扁豆等补后天以滋先天。试验证实结直肠癌接受FOLFIRI方案化疗的同时联合使用益肾健脾丸可以降低化疗后骨髓抑制的发生率,预防及治疗白细胞减少,减轻乏力、纳差、恶心、腹泻症状,提高肿瘤化疗患者的生活质量。Objective:To observe the clinical effect of Yishen Jianpi Wan(益肾健脾丸)in preventing and treating myelosuppression after FOLFIRI chemotherapy in colorectal cancer patients.Methods:Sixty patients with pathologically confirmed colorectal cancer who were admitted to the Department of Tumor Comprehensive Therapy in Sanming Hospital of Integrated Traditional Chinese and Western Medicine from August 1,2020 to April 1,2022 and received chemotherapy with FOLFIRI regimen were collected.Randomized number table method was used to divide the patients into 2 groups,with 30 cases in each group.The control group received FOLFIRI chemotherapy alone,and the experimental group received Yishen Jianpi Wan on the basis of chemotherapy.The changes of quality of life(KPS)score,TCM clinical syndrome score,peripheral blood white blood cells count(WBC),platelets count(PLT)and hemoglobin(HGB)were compared between the two groups before and 7 days after chemotherapy.Results:After treatment,there were differences in KPS and TCM clinical syndrome scores between the two groups(P<0.05),and the experimental group was better than the control group.After treatment,there was a statistically significant difference in blood routine WBC between the two groups(P<0.05),and the decrease of WBC in the experimental group was less,while the HGB and PLT levels were not significantly different before and after treatment(P>0.05).The overall incidence of myelosuppression was lower in the experimental group.Conclusion:The pathogenesis of myelosuppression after chemotherapy is mainly deficiency.The treatment can promote blood metaplasia and stimulate bone marrow hematopoietic by promoting spleen and stomach and tonifying liver and kidney.Yishen Jianpi Wan combines Yin and Yang of Bajitian(Morinda officinalis),Tusizi(Cuscuta chinensis),Nvzhenzi(Ligustrum lucidum),Huangjing(Rhizoma polygonatum)and other ingredients,and combines Taizishen(Radix Pseudostellariae),Gancao(Liquorice),Fuling(Poria cocos),Baizhu(Atractylodes macrocephala),Doukou(cardamom),and Biando

关 键 词：肠癌 骨髓抑制 健脾益肾 疗效 

分 类 号：R735[医药卫生—肿瘤]